Martin Fussenegger

Department of Biosystems Science and Engineering (D-BSSE), ETH Zürich


ETH Zürich

Department of Biosystems Science and Engineering (D-BSSE)
Mattenstrasse 26
4058 Basel
Office phone +41 61 387 31 60

Read more about the Fussenegger-Group here.


H. Wang, M. Xie, G. Charpin-El Hamri, H. Ye, M. FusseneggerTreatment of chronic pain by designer cells controlled by spearmint aromatherapy“ Nat. Biomed. Eng. (2018). [Link]
S. Ausländer, X. Pierrat, L. Hellmann, L. Rachid, M. FusseneggerProgrammable full-adder computations in communicating three-dimensional cell cultures“ Nat. Methods (2017). [Link]
R. Kojima, L. Scheller, M. FusseneggerNonimmune cells equipped with T-cell-receptor-like signaling for cancer cell ablation“ Nat. Chem. Biol. (2017). [Link]
V. Haellman, M. FusseneggerSynthetic biology – Engineering cell-based biomedical devices“ Curr. Opin. Biomed. Eng. (2017). [Link]
P. Saxena, D. Bojar, H. Zulewski, M. FusseneggerGeneration of glucose-sensitive insulin-secreting beta-like cells from human embryonic stem cells by incorporating a synthetic lineage-control network“ J. Biotechnol. (2017). [Link]
M. Xie, D. Aubel, M. FusseneggerClosed-loop control systems – The quest for precision therapies for diabetes“ Curr. Opin. Syst. Biol. (2017). [Link]
A. P. Teixeira, M. FusseneggerSynthetic biology-inspired therapies for metabolic diseases“ Curr. Opin. Biotechnol. (2017). [Link]
D. Ausländer, M. FusseneggerSynthetic Biology‐The Synthesis of Biology“ Angew. Chem. Int. Ed. 56, 6396-419 (2017). [Link]
S. Ausländer, M. FusseneggerSynthetic RNA-based switches for mammalian gene expression control“ Curr. Opin. Biotechnol. 48, 54-60 (2017). [Link]
M. Muller, D. Auslander, A. Spinnler, J. Sikorski, M. Folcher, M. FusseneggerDesigned cell consortia as fragrance-programmable analog-to-digital converters“  13, 309-16 (2017). [Link]
M. Xie, H. Ye, H. Wang, G. Charpin-El Hamri, C. Lormeau, P. Saxena, J. StellingM. Fusseneggerβ-cell–mimetic designer cells provide closed-loop glycemic control“ Science 354, 1296-1301 (2016). [Link]
R. Kojima, D. Aubel, M. FusseneggerToward a world of theranostic medication: Programming biological sentinel systems for therapeutic intervention“ Adv. Drug Delivery Rev. 105, 66-76 (2016). [Link]
M. Xie, V. Haellman, M. FusseneggerV. HällmanSynthetic biology-application-oriented cell engineering.“ Curr. Opin. Biotechnol. 40, 139 (2016). [Link]
P. Saxena, B. C. Heng, P. Bai, M. Folcher, H. Zulewski, M. FusseneggerA programmable synthetic lineage-control network that differentiates human IPSCs into glucose-sensitive insulin-secreting beta-like cells“ Nat. Commun. 7, DOI:10.1038/ncomms11247 (2016). [Link] [More Information]
P. Bai, H. Ye, M. Xie, P. Saxena, H. Zulewski, G. Charpin-El Hamri, V. Djonov, M. FusseneggerA synthetic biology-based device prevents liver injury in mice“ J. Hepatol. 65, 84 (2016). [Link]
D. Auslaender, D. W. Fuchs, S. Huerlemann, M. FusseneggerEngineering a ribozyme cleavage-induced split fluorescent aptamer complementation assay“ Nucleic Acids Res. 44, e94 (2016). [Link]
A. Tastanova, A. Schulz, A. Tolstrup, A. Puklowski, H. Kaufmann, M. FusseneggerOverexpression of YY1 increases the protein production in mammalian cells“ J. Biotechnol. 219, 72 (2016). [Link]
P. Saxena, G. Charpin-El Hamri, M. Folcher, H. Zulewski, M. FusseneggerSynthetic gene network restoring endogenous pituitary-thyroid feedback control in experimental Graves' disease“ Proc. Natl. Acad. Sci. U.S.A. 113, 1244 (2016). [Link]
B. Geering, Z. Zokouri, S. Hurlemann, B. Gerrits, D. Auslander, A. Britschgi, M. P. Tschan, H. U. Simon, M. FusseneggerIdentification of Novel Death-Associated Protein Kinase 2 Interaction Partners by Proteomic Screening Coupled with Bimolecular Fluorescence Complementation“ Mol. Cell. Biol. 36, 132-43 (2016). [Link]
L. Lina Schukur, B. Geering, G. Charpin-El Hamri, M. FusseneggerImplantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis“ Sci. Transl. Med. 7, DOI: 10.1126/scitranslmed.aac4964 (2015). [Link]
B. C. Heng, D. Aubel, M. FusseneggerProsthetic gene networks as an alternative to standard pharmacotherapies for metabolic disorders“ Curr. Opin. Biotechnol. 35, 37-45 (2015). [Link]
L. Schukur, B. Geering, M. FusseneggerHuman whole-blood culture system for ex vivo characterization of designer-cell function“ Biotechnol. Bioeng. 113, 588 (2015). [Link]
V. Haellman, M. FusseneggerV. HällmanSynthetic Biology-Toward Therapeutic Solutions“ J. Mol. Biol. 428, 945 (2015). [Link]
H. Wang, H. Ye, M. Xie, M. Daoud El-Baba, M. FusseneggerCosmetics-triggered percutaneous remote control of transgene expression in mice“ Nucleic Acids Res. 43, e91 (2015). [Link]
R. Kojima, D. Aubel, M. FusseneggerNovel theranostic agents for next-generation personalized medicine: small molecules, nanoparticles, and engineered mammalian cells“ Curr. Opin. Chem. Biol. 28, 29 (2015). [Link]
M. Xie, M. FusseneggerMammalian designer cells: Engineering principles and biomedical applications.“ Biotechnol. J. 10, 1005 (2015). [Link]
T. Kim, M. Folcher, M. Doaud-El Baba, M. FusseneggerA Synthetic Erectile Optogenetic Stimulator Enabling Blue-Light-Inducible Penile Erection“ Angew. Chem. Int. Ed. 54, 5933 (2015). [Link] [More Information]
T. Kim, M. Folcher, G. Charpin-El Hamri, M. FusseneggerA synthetic cGMP-sensitive gene switch providing Viagra((R))-controlled gene expression in mammalian cells and mice“ Metab. Eng. 29, 169-79 (2015). [Link]
B. Geering, M. FusseneggerSynthetic immunology: modulating the human immune system“ Trends Biotechnol. 33, 65-79 (2015). [Link]